T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$18.7B |
| 2 |
Apple
AAPL
|
+$5.48B |
| 3 |
NVIDIA
NVDA
|
+$5.33B |
| 4 |
Tesla
TSLA
|
+$4.47B |
| 5 |
Microsoft
MSFT
|
+$2.15B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$4.26B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.3B |
| 3 |
Morgan Stanley
MS
|
+$2.82B |
| 4 |
Global Payments
GPN
|
+$2.43B |
| 5 |
PayPal
PYPL
|
+$2B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.36% |
| 2 | Healthcare | 16.09% |
| 3 | Consumer Discretionary | 15.79% |
| 4 | Communication Services | 12.38% |
| 5 | Financials | 10.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2351
Standard Motor Products
SMP
$877M
| $528K | ﹤0.01% |
10,069
-319
| -3% | -$16K |
|
|
RVNC
2352
DELISTED
Revance Therapeutics, Inc.
RVNC
| $528K | ﹤0.01% |
32,353
+7,608
| +31% | +$127K |
|
2353
Evotec
EVO
$778M
| $527K | ﹤0.01% |
+22,188
| New | +$517K |
|
2354
Praxis Precision Medicines
PRAX
$10.8B
| $527K | ﹤0.01% |
1,782
+398
| +29% | +$117K |
|
|
MDRX
2355
DELISTED
Veradigm Inc. Common Stock
MDRX
| $527K | ﹤0.01% |
28,590
-32,666
| -53% | -$519K |
|
|
TRST
2356
Trustco Bank Corp NY
TRST
$963M
| $526K | ﹤0.01% |
15,797
+2,700
| +21% | +$89.7K |
|
|
SILK
2357
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $526K | ﹤0.01% |
12,338
+2,375
| +24% | +$119K |
|
2358
CALL
AstraZeneca
AZN
$244B
| $524K | ﹤0.01% |
4,750
-7,000
| -60% | -$824K |
|
|
RMO
2359
DELISTED
Romeo Power, Inc.
RMO
| $523K | ﹤0.01% |
143,339
+133,003
| +1,287% | +$574K |
|
|
HSKA
2360
DELISTED
Heska Corp
HSKA
| $522K | ﹤0.01% |
2,862
-165
| -5% | -$32.8K |
|
2361
Cimpress
CMPR
$2.4B
| $521K | ﹤0.01% |
7,280
-241
| -3% | -$19.7K |
|
|
PPSI
2362
Pioneer Power Solutions
PPSI
$34.1M
| $521K | ﹤0.01% |
69,400
+33,600
| +94% | +$203K |
|
2363
Interface
TILE
$2.23B
| $521K | ﹤0.01% |
32,634
+6,495
| +25% | +$101K |
|
|
SRNE
2364
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $520K | ﹤0.01% |
111,906
+9,933
| +10% | +$61.7K |
|
2365
Verra Mobility
VRRM
$714M
| $519K | ﹤0.01% |
33,644
-1,488
| -4% | -$22.6K |
|
2366
AudioCodes
AUDC
$249M
| $517K | ﹤0.01% |
14,869
| – | – |
|
2367
Mastech Digital
MHH
$92.7M
| $517K | ﹤0.01% |
30,284
| – | – |
|
|
PRSU
2368
Pursuit Attractions and Hospitality Inc
PRSU
$1.27B
| $517K | ﹤0.01% |
12,091
-358
| -3% | -$16.4K |
|
2369
Universal Electronics
UEIC
$75.8M
| $515K | ﹤0.01% |
12,647
+1,740
| +16% | +$72K |
|
2370
Enovix
ENVX
$966M
| $513K | ﹤0.01% |
+21,486
| New | +$520K |
|
2371
Caleres
CAL
$455M
| $511K | ﹤0.01% |
22,528
-600
| -3% | -$14.3K |
|
2372
Healthcare Services Group
HCSG
$1.43B
| $511K | ﹤0.01% |
28,731
-1,400
| -5% | -$27.2K |
|
2373
Willdan Group
WLDN
$1.29B
| $502K | ﹤0.01% |
14,275
-153
| -1% | -$5.7K |
|
2374
Stewart Information Services
STC
$2B
| $501K | ﹤0.01% |
6,287
-1,056
| -14% | -$77.6K |
|
2375
National Beverage
FIZZ
$2.9B
| $499K | ﹤0.01% |
11,017
-987
| -8% | -$53.7K |
|
Similar funds
T. Rowe Price Associates's Q4 2021 Portfolio in Review
As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
- T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
- T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
- T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
- T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
- T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.